The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
Washington, DC
Joined December 2008
- Tweets29.8K
- Following614
- Followers103K
- Likes434
FierceBiotech retweeted
Enhertu has transformed HER2 breast cancer treatment and set a high bar for the next generation of drugs. Now, the race is on to develop something even better, but finding a worthy successor is proving to be easier said than done. fiercebiotech.com/biotech/ad…
Our annual Biotech Graveyard returns to remember the drug developers that shut their doors this year and the science that may yet live on. fiercebiotech.com/biotech/20…
Zentalis is already preparing for a potential U.S. launch of its WEE1 inhibitor azenosertib after encouraging ovarian cancer data at ESMO. CEO Julie Eastland tells Fierce why the biotech sees a commercial opportunity. fiercebiotech.com/biotech/es… #ESMO26
The U.S. Treasury is proposing new restrictions on investments in Chinese biotech, but traditional pharma licensing deals would largely be spared. Equity investments and certain partnerships could face significant hurdles. fiercebiotech.com/biotech/tr…
FierceBiotech retweeted
🎧 This week on "The Top Line": GSK's pair of FDA approvals, Roche's $15 billion ADC deal and the rise of point-of-care pharma marketing. fiercepharma.com/pharma/gsks…
Roche is building its blockbuster case for MS hopeful fenebrutinib, unveiling new data on brain lesions, disability progression and brain volume loss as the BTK inhibitor advances toward an FDA decision. fiercebiotech.com/biotech/ro…
After a turbulent period at the FDA, CBER Director Karim Mikhail tells Fierce he's focused on restoring stability, rebuilding morale and rethinking rare disease regulation. "I'm not going to hide," he said. fiercebiotech.com/biotech/cb…
Pfizer has ended a phase 2 trial of its autoimmune drug PF-06835375, citing a "business decision" unrelated to safety. fiercebiotech.com/biotech/pf…
How did Hengrui become a go-to source of Chinese biopharma innovation? After multibillion-dollar deals with BMS and GSK, the company's R&D leader tells Fierce what's driving its success and where it goes next. fiercebiotech.com/biotech/he…
AbbVie may have found a way to improve on its blockbuster Skyrizi. fiercebiotech.com/biotech/ab… $ABBV
Nouscom has secured $135 million to advance its cancer-preventing vaccine into a pivotal trial. fiercebiotech.com/biotech/no…
Merck KGaA is buying Silence Therapeutics for $1.3 billion, picking up a promising siRNA candidate for a rare blood cancer following its phase 2 success. fiercebiotech.com/biotech/me…
Roche is doubling down on China's Hansoh Pharma with a new ADC deal worth up to $15 billion in milestones. The pact comes just a year after the companies' first collaboration. fiercebiotech.com/biotech/ro… $ROCH.NE
OrbiMed has raised $3 billion for new life sciences investments, including more than $1 billion for its largest-ever Asia fund, as investor interest in the region's biotech sector continues to grow. fiercebiotech.com/biotech/or…
With $310 million in fresh funding, former Fierce 15 winner OMass Therapeutics is one step closer to its goal of becoming "Britain's Big Biotech." CEO Ros Deegan tells Fierce what's next for the ambitious biotech. fiercebiotech.com/biotech/wh…
Verdiva Bio has scrapped a phase 2 trial of its once-weekly oral GLP-1 drug candidate VRB-101. fiercebiotech.com/biotech/de…
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline fiercebiotech.com/biotech/ze…
Looking to expand its oncology portfolio, Gilead Sciences has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal. fiercebiotech.com/biotech/gi…
Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar data fiercebiotech.com/biotech/ze…
Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing total lung capacity. fiercebiotech.com/biotech/en…
